Shields JA - Search Results

1

VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.

Shields JA, Meier SR, Bandi M, Mulkearns-Hubert EE, Hajdari N, Ferdinez MD, Engel JL, Silver DJ, Shen B, Zhang W, Hubert CG, Mitchell K, Shakya S, Zhao SC, Bejnood A, Zhang M, Tjin Tham Sjin R, Wilker E, Lathia JD, Andersen JN, Chen Y, Li F, Weber B, Huang A, Emmanuel N. Shields JA, et al. Cancer Res. 2022 Nov 2;82(21):4044-4057. doi: 10.1158/0008-5472.CAN-21-4443. Cancer Res. 2022. PMID: 36069976 Free PMC article.

2

Association between telomerase activity and basic fibroblast growth factor up-regulation in retinoblastomas.

Kondo Y, Tanaka Y, Shields JA, Kondo S. Kondo Y, et al. Among authors: shields ja. Anticancer Res. 2001 Nov-Dec;21(6A):3765-72. Anticancer Res. 2001. PMID: 11911245

3

Non-Conditional and Conditional Metastasis of Uveal Melanoma Per Millimeter-By-Millimeter in Thickness in 8034 Patients.

Sener H, Bansal R, Catapano T, Shields JA, Shields CL. Sener H, et al. Among authors: shields ja. Semin Ophthalmol. 2024 Nov 24:1-8. doi: 10.1080/08820538.2024.2432907. Online ahead of print. Semin Ophthalmol. 2024. PMID: 39580712

4

Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease.

Feys JR, Edwards K, Joyce MA, Saffran HA, Shields JA, Garcia K, Tyrrell DL, Fischer C. Feys JR, et al. Among authors: shields ja. ACS Med Chem Lett. 2024 Nov 3;15(11):2046-2052. doi: 10.1021/acsmedchemlett.4c00444. eCollection 2024 Nov 14. ACS Med Chem Lett. 2024. PMID: 39563811

5

High-Dose Intravitreal Topotecan for Recurrent Retinoblastoma, Subretinal Seeds, and Vitreous Seeds in 13 Consecutive Cases.

Shields CL, Medina R, Evans H, Valdes-Perez N, Burak A, Bansal R, Lally SE, Shields JA. Shields CL, et al. Among authors: shields ja. Retina. 2024 Oct 1. doi: 10.1097/IAE.0000000000004283. Online ahead of print. Retina. 2024. PMID: 39378373

6

Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases.

Bansal R, Sener H, Ganguly A, Shields JA, Shields CL. Bansal R, et al. Among authors: shields ja. Clin Exp Ophthalmol. 2024 Oct 4. doi: 10.1111/ceo.14446. Online ahead of print. Clin Exp Ophthalmol. 2024. PMID: 39364722

7

Predicting Choroidal Nevus Transformation to Melanoma Using Machine Learning.

Tailor PD, Kopinski PK, D'Souza HS, Leske DA, Olsen TW, Shields CL, Shields JA, Dalvin LA. Tailor PD, et al. Among authors: shields ja. Ophthalmol Sci. 2024 Jul 20;5(1):100584. doi: 10.1016/j.xops.2024.100584. eCollection 2025 Jan-Feb. Ophthalmol Sci. 2024. PMID: 39318711 Free PMC article.

8

Large Language Models in Ophthalmology: Potential and Pitfalls.

Yaghy A, Yaghy M, Shields JA, Shields CL. Yaghy A, et al. Among authors: shields ja. Semin Ophthalmol. 2024 May;39(4):289-293. doi: 10.1080/08820538.2023.2300808. Epub 2024 Jan 5. Semin Ophthalmol. 2024. PMID: 38179986 Review.

9

Understanding choroidal nevus risk factors for transformation into melanoma.

DeSimone JD, Shields CN, Kalafatis NE, Marous MR, Marous CL, Shields JA, Shields CL. DeSimone JD, et al. Among authors: shields ja. Clin Dermatol. 2024 Jan-Feb;42(1):38-45. doi: 10.1016/j.clindermatol.2023.10.012. Epub 2023 Oct 20. Clin Dermatol. 2024. PMID: 37866411

10

Conjunctival melanoma: Insights into classification, outcomes, and biomarkers.

Shields CL, Silva AMV, Laiton A, Kalafatis NE, Schiller E, Lally SE, Grant-Kels JM, Shields JA. Shields CL, et al. Among authors: shields ja. Clin Dermatol. 2024 Jan-Feb;42(1):46-55. doi: 10.1016/j.clindermatol.2023.10.010. Epub 2023 Oct 18. Clin Dermatol. 2024. PMID: 37858779

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,365 results

Search Page

Filters